| Safety and regulation
Update, October 30, 2026: HHS has since issued the policy. It made the document public on October 28, and the Federal Register published its notice on October 30. It names six peptides, it is not an FDA approval, and it is not binding. Read the full report, HHS names six peptides in new compounding policy, and see the updated peptide policy tracker.
A law-firm review and a STAT report say a draft interim policy for compounding certain peptides, including BPC-157, was sent to the White House Office of Management and Budget on October 14, 2026. Sources familiar with the plan told STAT it would let pharmacies compound some peptides for a time without FDA enforcement.
As of October 14, it had not been issued, and its contents were not public.
Worth knowing: The draft would not have been an FDA approval of any peptide, and FDA staff recommended against adding the peptides reviewed in July.
Related: Peptide policy tracker | What a 503A pharmacy is
Source: STAT News, October 15, 2026. News report Trade press, secondary source. Holland & Knight law-firm alert, October 16, 2026. Secondary source Trade press, secondary source.